Lannett Confident Of $1bn In Sales By 2025
Lantus And Advair Among Key Projects
US-centric generics player Lannett has an ambitious sales and profitability goals for the next five years, driven by several rewarding pipeline opportunities and a leaner cost base. CEO Tim Crew told investors of Lannett’s plans as he presented year-end financial results
